Sept. 14, 2026
Biotech Correspondent
Meghana Keshavan covers biotech and contributes toThe Readout newsletter.
Want to stay on top of the science and politics driving biotech today?Sign upto get our biotech newsletter in your inbox.
Definium’s LSD therapy has a strong performacne in a pivotal anxiety trial, drugmaker deals could gut “most-favored nation” Medicare savings, and more.
Advertisement
In this endless heat wave my house is now overrun with flies and I think I give up and will also become a fly. They win.
STAT+ Exclusive Story
Already have an account?Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account?Log in
Monthly
$39
Totals $468 per year
$39/monthGet StartedTotals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 monthsGet StartedThen $399/year
Annual
$399
Save 15%
$399/yearGet StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A QuoteRequest A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/yearGet Started$300 Annually per user
View All PlansTo read the rest of this story subscribe to STAT+.
SubscribeLog Inbiotechnology,
drug development,
Drug prices,
researchSubmit a correction requestReprintsBiotech Correspondent
Meghana Keshavan covers biotech and contributes toThe Readout newsletter.
Newsletter
Understand how science, health policy, and medicine shape the world every day
